Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC13A5 | Q86YT5 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20258827 | 0.89 | SLC13A5 (0.69) | SLC13A5ALDH1A1POLBTP53EPHX2 | |
| SCHEMBL20258662 | 0.88 | SLC13A5 (0.80) | SLC13A5ALDH1A1POLBTP53EPHX2 | |
| SCHEMBL21766086 | 0.88 | TP53 (0.62) | SLC13A5ALDH1A1POLBTP53EPHX2 | |
| SCHEMBL21765930 | 0.86 | SLC13A5 (0.82) | SLC13A5ALDH1A1POLBTP53EPHX2 | |
| SCHEMBL21766032 | 0.86 | SLC13A5 (0.77) | SLC13A5ALDH1A1POLBTP53MEN1 | |
| SCHEMBL21766012 | 0.80 | SLC13A5 (0.85) | SLC13A5ALDH1A1POLBTP53EPHX2 | |
| SCHEMBL21766082 | 0.80 | TP53 (0.66) | SLC13A5ALDH1A1POLBTP53EPHX2 | |
| SCHEMBL21766044 | 0.80 | SLC13A5 (0.65) | SLC13A5ALDH1A1POLBTP53EPHX2 | |
| SCHEMBL20258826 | 0.79 | TSHR (0.79) | ALDH1A1POLBMEN1KMT2ALMNA | |
| SCHEMBL21766078 | 0.77 | KMT2A (0.58) | SLC13A5ALDH1A1TP53MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10793522-B2 | Sulfonamides as inhibitors of the uptake of extracellular citrate | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-10-06 | — | — | US | disclosed |
| EP-3551618-B1 | SULFONAMIDES AS INHIBITORS OF THE UPTAKE OF EXTRACELLULAR CITRATE | BOEHRINGER INGELHEIM INT (DE) | 2020-09-16 | — | — | EP | disclosed |
| US-20200062708-A1 | SULFONAMIDES AS INHIBITORS OF THE UPTAKE OF EXTRACELLULAR CITRATE | BOEHRINGER INGELHEIM PHARMA GBMH & CO KG (DE) | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062708-A1 | SULFONAMIDES AS INHIBITORS OF THE UPTAKE OF EXTRACELLULAR CITRATE | CS, GLS, GLS2 | SLC13A5 261/4885ALDH1A1 732/4885POLB 2442/4885 |
| US-10793522-B2 | Sulfonamides as inhibitors of the uptake of extracellular citrate | CS, GLS, GLS2 | SLC13A5 261/4885ALDH1A1 732/4885POLB 2442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.